Results 11 to 20 of about 33,645 (162)
Amiodarone Hepatotoxicity [PDF]
Current Vascular Pharmacology, 2008 Potential hepatotoxicity related to amiodarone therapy is often a concern when deciding whether to initiate or continue treatment with this medication. While mostly associated with long-term oral administration of the drug, toxicity has also been reported early during intravenous administration and months after discontinuation of therapy.
Mohamed, Babatin +2 more
openaire +4 more sources
Pharmaceutics, 2022 Background: Adjusting drug therapy under veno-venous extracorporeal membrane oxygenation (VV ECMO) is challenging. Although impaired pharmacokinetics (PK) under VV ECMO have been reported for sedative drugs and antibiotics, data about amiodarone are ...
Mickaël Lescroart +9 more
doaj +1 more source
Medical and Health Science Journal, 2019 A woman, 53 years of age, with recurrent supraventricular tachycardia (SVT) with hypothyroidism was thought to be associated with amiodarone use. Patients repeatedly get amiodarone for their arrhythmias, where amiodarone has a broad antiarrhythmic
,Ardyarini Dyah Savitri
doaj +1 more source
Clinical and Translational Science, 2022 Amiodarone and its main metabolite, desethylamiodarone (DEA), are highly distributed to serum lipoproteins such as very‐low‐density lipoprotein (VLDL) and low‐density lipoprotein (LDL), which are the carriers of triglyceride and cholesterol.
Naoaki Hashimoto +5 more
doaj +1 more source
Amiodarone-related Pneumonitis
Journal of the Formosan Medical Association, 2007 Amiodarone-related pneumonitis is a potentially limiting factor for amiodarone usage. However, it is believed that amiodarone-related pneumonitis is unlikely to occur during low-dose and short courses of therapy. We report three patients who received low-
Sheng-Nan Chang +7 more
doaj +1 more source
Diagnostics, 2022 Amiodarone hydrochloride is an antiarrhythmic drug, with proven efficacy in prevention and treatment of numerous arrhythmias, atrial fibrillation especially, or ventricular arrhythmias, with a long half-life (55–60 days). The increased risk of developing
Corina Eugenia Budin +6 more
doaj +1 more source
Lipid emulsion mitigates intravenous amiodarone toxicity in a rat model
Toxicology Communications, 2022 Introduction Our study investigated whether lipid emulsion therapy could act as an antidote for intravenous amiodarone toxicity in a rat model.Methods 20 rats were randomised to receive lipid emulsion (ILE) or saline. Rats were infused with amiodarone at
Rachael Stewart +5 more
doaj +1 more source
Journal of the Formosan Medical Association, 2023 Background/purpose: Amiodarone increases exposure of direct oral anticoagulants (DOACs). We aimed to analyze the effects of concurrent amiodarone use on DOAC concentrations and clinical outcomes.
Shin-Yi Lin +7 more
doaj +1 more source
Journal of the Belgian Society of Radiology, 2010 Background: A 65-year-old male patient presented with progressive shortness of breath over the past 3 months, recently even at rest. He neither complained about fever nor about chest pain. The laboratory findings were normal with only a slight increase in leucocytes. A significant restrictive ventilation disorder was noted on plethysmography.
Bley, T A, François, C J
openaire +5 more sources
Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports
Journal of Medical Case Reports, 2018 Background Amiodarone is a highly effective treatment for supraventricular and ventricular tachyarrhythmia; however, it could be associated with several serious adverse effects, including liver injury.
Toyonobu Tsuda +12 more
doaj +1 more source